- Merck KGaA (OTCPK:MKGAY) will collaborate with French outfit Iktos, leveraging the latter's generative modeling artificial intelligence (AI) technology in drug discovery and design.
- According the Iktos, its AI technology enables a more rapid and efficient drug discovery process by automating the design of virtual molecules with the desired attributes for treating a given disease.
- Financial terms are not disclosed.